Petros Pharmaceuticals is committed to the goal of becoming a leading innovator in the emerging self-care market driving expanded access to key prescription pharmaceuticals as Over-the-Counter treatment options.
At Petros Pharmaceuticals, that’s the world towards which we are working.
Petros Pharmaceuticals is dedicated to pioneering innovation in the burgeoning self-care sector. Our mission is to propel increased availability of essential prescription pharmaceuticals by transforming them into Over-the-Counter treatment alternatives, ultimately striving to lead this transformative market.
households would let their sickness run its course without treatment if over-the-counter medicines weren’t available
of consumers would have gone to the doctor instead if over-the-counter medicines weren’t available
Over-the-counter medicines save the US healthcare system $167B annually
We are committed to creating a world where people can obtain access to appropriate conducive medications without the need for a physician and prescription.
Currently, Petros is pursuing increased access to its flagship prescription ED therapy via potential OTC designation. If ultimately approved by the FDA for OTC access, this therapy may be the first in its class to achieve this marketing status, also establishing company know-how as a proven platform for the development of other prospective prescription therapeutics.
We are developing the first OTC prescription-grade therapeutic option for erectile dysfunction(ED).
Vacuum Therapy Systems have helped millions of men manage their Erectile Dysfunction.
Mr. Weinstein joined Petros as its acting Chief Financial Officer, upon the merger of Metuchen Pharmaceuticals, LLC with Neurotrope, Inc., in December 2020. He is also currently the Chief Financial Officer of Synaptogenix, Inc., a biotechnology company pursuing various neurological therapeutics including Alzheimer’s disease.
He has extensive accounting and finance experience, spanning almost 40 years, as a public accountant, investment banker, healthcare private equity fund principal and chief financial officer. From September 2011 to the present, Mr. Weinstein has been an independent consultant for several healthcare companies in the pharmaceutical and biotechnology industries. From March 2010 to August 2011, he was the Chief Financial Officer of Green Energy Management Services Holdings, Inc., a publicly-traded energy consulting company. From August 2007 to February 2010, Mr. Weinstein served as Chief Financial Officer of Xcorporeal, Inc., a publicly-traded, development-stage medical device company which was sold in March 2010 to Fresenius Medical USA, the largest provider of dialysis equipment and services worldwide.
Mr. Weinstein also serves as a member of the Board of Directors and the Chairman of the Audit Committee of XpresSpa Group, Inc. (Nasdaq: XSPA), a health and wellness company whose core assets, XpresCheck and XpresSpa, operate several Covid testing facilities in major US airports and is a leading retailer of spa services and related health and wellness products.
Mr. Weinstein received his MBA degree in finance and international business from the University of Chicago Graduate School of Business, is a Certified Public Accountant (inactive), and received his BS degree in accounting from the State University of New York at Albany.
Mitchell Arnold has served as the Vice President of Finance and Chief Accounting Officer of Petros since 2021. Mr. Arnold has served as Vice President of Finance of the Company since 2019.
Mr. Arnold brings to the Company over 30 years of experience in organizational leadership in finance and accounting roles at both public and private companies, where he was successful in improving financial performance, cash flows, accounting processes, SOX compliance and ERP systems.
Prior to joining the Company, from 2011 to 2018, Mr. Arnold served as Vice President of Financial Accounting at Akrimax Pharmaceuticals, LLC where he provided strategic guidance of accounting and finance, treasury management, risk management and insurance, information technology and facilities management. Mr. Arnold holds a Master of Business Administration degree in Finance from Temple University and a Bachelor of Science degree in Accounting from Pennsylvania State University.
Bruce T. Bernstein has over thirty years of experience in the securities industry, primarily as a senior portfolio manager for two alternative finance funds as well as a deep understanding of the trading and structuring of arbitrage strategies.
Since 2006, Mr. Bernstein has served as President of Rockmore Capital, LLC, a direct investment and lending fund. Previously, Bruce served as Co-President of Omicron Capital, LP, an investment firm based in New York. Prior to joining Omicron Capital, Mr. Bernstein was with Fortis Investments Inc. where he served as a Senior Vice President in the bank`s Global Securities Arbitrage business unit and then President in charge of the bank`s proprietary investment business in the United States. Mr. Bernstein also serves as a member of the board of directors of XpresSpa Holdings, the leading airport spa company in the world.
Mr. Bernstein is also a member of the board of Summit Digital Health, a laser based blood glucose monitor distributor. Mr. Bernstein holds a B.B.A. from City University of New York (Baruch).
Mr. Walker founded Walker Nell Partners, Inc. (“Walker Nell”), a financial advisory firm in 2013, where he continues to serve as the managing partner.
Walker Nell provides corporate governance and restructuring advisory services, fiduciary services, litigation support, and other services to client corporations and law firms. In his role at Walker Nell, he has served on a number of private company boards.
He currently serves as Chairman of the Board of Trustees of National Philanthropic Trust, a public charity that holds over $6 billion of assets under management. Mr. Walker has more than 25 years of experience in corporate law and corporate restructuring, including working 15 years at the DuPont Company.
Greg Bradley joined Foundation Consumer Healthcare as CEO in October of 2017. Greg has 34 years of experience in the consumer-packaged goods industry with a specific expertise in OTC Healthcare.
He has a proven track record in Sales, Marketing, Supply Chain and General Management. Prior to joining Foundation CH, Greg spent much of his career with GlaxoSmithKline Consumer Healthcare (GSK) in senior management roles where he helped create several mega brands within the OTC healthcare landscape, including multiple Rx-OTC switches.
In 2011, Greg founded Advantage Consumer Healthcare (ACH), a full-service company specializing in OTC switches, Healthcare product launches and improving in-market performance of existing OTC Healthcare brands.
Mr. Silverman is the Co–founder and Managing Member of Parkfield Funding LLC, and is a former Principal and Managing Partner of Iroquois Capital Management, LLC.
Mr. Silverman served as Co–Chief Investment Officer of Iroquois from 2003 until July 2016. From 2000 to 2003, Mr. Silverman served as Co–Chief Investment Officer of Vertical Ventures, LLC, a merchant bank. Prior to forming Iroquois, Mr. Silverman was a Director of Joele Frank, a boutique consulting firm specializing in mergers and acquisitions.
Previously, Mr. Silverman served as Assistant Press Secretary to The President of The United States. Mr. Silverman received his B.A. from Lehigh University in 1992. In the past five years, Mr. Silverman has served as a director of MGT Capital Investments, Inc. and National Holdings Corporation.
John Shulman is Founder and Managing Partner of Juggernaut Capital Partners, a leading private equity firm with over $1 billion in committed capital.
Mr. Shulman currently serves on the Boards of Directors of Metuchen Pharmaceuticals (Rx Pharmaceuticals) and Foundation Consumer Healthcare (OTC Pharmaceuticals). Previously, he served on the Boards of Directors of Triax Pharmaceuticals (Rx Pharmaceuticals) and Insight Pharmaceuticals (OTC Pharmaceuticals).
Mr. Shulman holds a B.S. degree in Finance from The McIntire School of Commerce at the University of Virginia.
Mr. Boctor has over 20 years of experience in the pharmaceutical industry, across a wide array of functions including brand and portfolio marketing, sales channel optimization, product portfolio strategy development and new product launches.
Mr. Boctor has driven significant revenue growth for specialty biologics, mainstream Men’s Health product lines, rare/orphan disease therapeutics, and substance abuse rescue modalities. Mr. Boctor has worked for companies such as Novartis, Forest Pharmaceuticals, Auxilium Pharmaceuticals, Endo Pharmaceuticals and Adapt Pharmaceuticals (Emergent Biosolutions). Mr. Boctor has his BA in International Relations from Hamline University, Masters in Diplomacy from Norwich University and his MBA from the University of Manchester Business School.